Selank
Half-life
3 min
Time to Peak
2 min
Steady State
~1 days
Dose Range
150–750 mcg
Frequency
Daily
Overview
Synthetic anxiolytic peptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. A heptapeptide analog of the immunomodulatory peptide tuftsin with added Pro-Gly-Pro sequence for stability. Approved in Russia as an anxiolytic. Primarily administered intranasally; also used subcutaneously. Very short half-life. Requires reconstitution with BAC water for injectable use.
Mechanism of Action
Modulates GABA, serotonin, and dopamine neurotransmission. Increases BDNF expression. Anxiolytic effects without sedation or cognitive impairment. Also modulates IL-6 expression.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Nasal | 150–750 mcg | 3 min | 2 min | Daily, Twice daily, three times daily |
| Subcutaneous (SubQ) | 150–750 mcg | 3 min | 2 min | Daily, Twice daily |
Storage & Handling
2-8C — Store refrigerated. Intranasal solution or reconstitute with BAC water for SubQ use.
Used in Regimens
1 regimenData Sources
- Peer-reviewed Selank anxiolytic peptide pharmacological profile
Related Tools
Track Selank with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.